Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for BI 3034701, a potential first-in-class anti-obesity drug. The molecule was originally developed by Denmark-based Gubra A/S (XCSE: GUBRA) and is a long-acting triple-agonist peptide designed to target receptors associated with inducing weight loss, positioning it as a promising next-generation obesity treatment. Boehringer Ingelheim entered into a partnership with Gubra in 2021 to identify anti-obesity candidates, with BI assuming full responsibility for the drug’s global development and commercialization.
The Phase I study (NCT06352437) is currently being conducted in Germany. This first-in-human, randomized, placebo-controlled trial aims to evaluate the safety, tolerability, and pharmacokinetics of BI 3034701. The trial is expected to enroll approximately 124 patients. Part A of the study will focus on healthy males between the ages of 18 and 55, while Part B will include individuals between 18 and 65 years of age who are overweight or obese but otherwise healthy. The study is anticipated to conclude in the second half of 2025.- Flcube.com
